Nelvys Subirós-Martínez

Nelvys Subirós-Martínez


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2012 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Closed access
NSNelvys Subirós-Martínez
Nelvys Subirós-Martínez
DBDiana García del Barco
Diana García del Barco
RCRosa M. Coro-Antich
Rosa M. Coro-Antich
Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thrombolytic, nonneuroprotective approach. An important neuroprotective strategy is based on erythropoietin (EPO). Exogenously administered EPO exhibits neuroprotective effects in numerous animal models, through the activation of anti-apoptotic, anti-oxidant and anti-inflammatory pathways as well as through the stimulation of angiogenic and neurogenic events. The capability of EPO to cross the blood–brain barrier after systemic administration and its effective therapeutic window are advantages for human acute stroke therapy. However, a multicenter stroke trial where recombinant human EPO (rhEPO) was combined with rtPA had negative outcomes. The present paper reviews the EPO neuroprotective strategy and its mechanisms in ischemic stroke and in other human nervous system diseases.

31 December 2012 in Acta Neurobiologiae Experimentalis
Verified
Journal Article
Open access
PDF file
NSNelvys Subirós-Martínez
Nelvys Subirós-Martínez
JMJorge Machado
Jorge Machado
HPHector Perez-Saad
Hector Perez-Saad
RCRosa Coro-Antich
Rosa Coro-Antich
JBJorge Berlanga-Acosta
Jorge Berlanga-Acosta
DBDiana Barco
Diana Barco
The Mongolian gerbil has been widely used as a global brain ischemia model because of its incomplete cerebral circle of Willis. However, the inter-individual anatomic variability of this vascular structure interferes with the reliability of the model. The aim of this work was to introduce modifications to the protocol of global brain ischemia experiments in Mongolian gerbils in an attempt to increase the reliability and usefulness of this model. Our study focused on the assessment of the level of anastomosis of the cerebral circle of Willis in order to evaluate its contribution to clinicopathological outcomes in this model. Sham-operated, Ischemic, and Ischemic + Hypothermia animals were subjected to a 15-minute occlusion of the common carotid arteries. Transcardiac perfusion with bromophenol blue / gelatin solution was performed 72 hours after ischemia. Brains were processed for anatomopathological analysis. Tissue damage was observed in the hippocampus, caudate-putamen nucleus, neocortex, and thalamic nuclei of animals from the Ischemic group. The circles of Willis of the Sham-operated animals showed bilateral (38 percent), unilateral (48 percent) or no posterior communicating arteries (14 percent). A negative correlation between infarct volume and the level of anastomosis was revealed for the Ischemic, but not for the Ischemic + Hypothermia group. Additionally, Analysis of covariance (ANCOVA) was performed to assess the contribution of the level of anastomosis to the clinicopathological outcomes. It was confirmed that the infarct volume decreased in the Ischemic + Hypothermia group when compared to the Ischemic group. Since the level of anastomosis cannot be predicted, this variable should necessarily be considered when analyzing the results of global brain ischemia in Mongolian gerbils.

1 January 2012
Verified
Journal Article
Closed access
NSNelvys Subirós-Martínez
Nelvys Subirós-Martínez
JMJorge Martín Machado
Jorge Martín Machado
HPHector Pérez-Saad
Hector Pérez-Saad
RCRosa M Coro-Antich
Rosa M Coro-Antich
JBJorge A Berlanga-Acosta
Jorge A Berlanga-Acosta
DBDiana García Del Barco
Diana García Del Barco

3 March 2016 in Neurological Research
Verified
Journal Article
Closed access
NSNelvys Subirós-Martínez
Nelvys Subirós-Martínez
HPHéctor Manuel Pérez-Saad
Héctor Manuel Pérez-Saad
JBJorge Amador Berlanga
Jorge Amador Berlanga
LALizet Aldana
Lizet Aldana
GGGerardo García-Illera
Gerardo García-Illera
DGDiana García-Del-Barco
Diana García-Del-Barco
Stroke continues to be a leading cause of mortality and morbidity worldwide, and novel therapeutic options for ischaemic stroke are urgently needed. In this context, drug combination therapies seem to be a viable approach, which has not been fully explored in preclinical studies. In this work, we assessed the dose–response relationship and therapeutic time window, in global brain ischaemia, of a combined therapeutic approach of recombinant human epidermal growth factor (EGF) and growth hormone-releasing peptide-6 (GHRP-6). Mongolian gerbils underwent 15 minutes occlusion of both common carotid arteries. Four different doses of rhEGF, GHRP-6 and combined agents were intraperitoneally administered immediately after the onset of reperfusion. Having identified a better response with both agents, rhEGF+GHRP-6 were administered at 2, 4, 6, 8 or 24 hours after the onset of reperfusion to assess the time window of effectiveness. Animals were evaluated daily for neurological deficits. Three days post-occlusion, the animals were sacrificed and 2,3,5-triphenyltetrazolium chloride was used to quantify infarcted tissues. The coadministration of rhEGF and GHRP-6 at doses of 100 and 600 μg/kg, respectively, administered up to 4 hours following the ischaemic insult, significantly improved survival and neurological outcome, and reduced infarct volume compared with vehicle treatment. These results are considered as an additional proof of concept as supporting a combined therapeutic approach and justify the further development of this preclinical research.

4 July 2026 in Neurotoxicity Research
Verified
Journal Article
Closed access
DRDaniela Risco-Acevedo
Daniela Risco-Acevedo
NSNelvys Subirós-Martínez
Nelvys Subirós-Martínez
HCHanlet Camacho-Rodríguez
Hanlet Camacho-Rodríguez
JRJeney Ramírez-Sánchez
Jeney Ramírez-Sánchez
YRYaima Rodríguez-Virulich
Yaima Rodríguez-Virulich
DBDiana Garcia-del- Barco
Diana Garcia-del- Barco

16 July 2026 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
FHFrancisco Hernández-Bernal
Francisco Hernández-Bernal
NSNelvys Subirós-Martínez
Nelvys Subirós-Martínez
JGJuan H. Gutiérrez-Ronquillo
Juan H. Gutiérrez-Ronquillo
ECElizabeth Colina-Ávila
Elizabeth Colina-Ávila
MGMarbelys Guevara-Rodríguez
Marbelys Guevara-Rodríguez
DBDiana Garcia-del- Barco
Diana Garcia-del- Barco